The Week in Review: March 9 – March 16, 2018

Friday, March 16, 2018 News Recap: Canada: Treatment: Fantastic news from both BC and Quebec this last week:  All restrictions to treatment under the respective provincial PharmaCare plans have been removed!! See Chronic hepatitis C medication now available for all British Columbians, and Quebec Expands Patient Access to Chronic Hepatitis C Therapies. Grants Awarded to 13 Canadian Initiatives to Help Advance the Goal of Eliminating Chronic Hep...

Chronic hepatitis C medication now available for all British Columbians

Any British Columbian living with chronic hepatitis C now is able to access treatment, regardless of the severity of their disease, Health Minister Adrian Dix announced today. In addition to expanding coverage to all British Columbians, a new chronic hepatitis C drug has been added to the PharmaCare formulary. “In years past, a hepatitis C diagnosis was a stressful and lifelong struggle,” said Dix. “I’m pleased to share that, as of today, anyone in B.C. l

Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan

Gilead applauds Ontario's Ministry of Health for expanding access to curative hepatitis C therapies to all diagnosed patients, regardless of severity of illness Ontario's expanded access includes EPCLUSA®, a 12 week treatment for patients with chronic hepatitis C across all six genotypes Gilead's new product, VOSEVI™ is now available under the Ontario Drug Benefit Program The removal of the fibrosis level criterion for access furthers C...

Colorado board recommends expanded coverage for hepatitis C drug

ACLU threatens lawsuit over coverage policy A state board recommended Tuesday night that more needy Coloradans receive potentially curative treatments for hepatitis C. But the board stopped short of recommending that the treatments — new drugs that have been shown to have a 90 percent cure rate — be extended to all Coloradans on Medicaid. And that means the American Civil Liberties Union may file a federal lawsuit against the state to force it to provi

U.S. FDA approves Gilead’s hepatitis C drug for expanded use

– Label Expanded to Include Patients with Genotypes 4, 5 and 6 and Patients Co-Infected with HIV –– Use of Harvoni in Combination with Ribavirin for 12 Weeks Can be Considered for Treatment-Experienced Genotype 1 Patients with Cirrhosis –FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 12, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Harvoni® (ledipasvir/sofosbuvir) for expanded use in